Comparing the current results to its competitors, Theriva Biologics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 77.91 %, recorded in the same quarter.
Theriva Biologics Inc 's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industries are competitive sectors with major multinational companies developing both generic and proprietary therapies. Many competitors possess greater resources and have established strategic collaborations with larger industry players, enhancing their capabilities in research, development, and commercialization. Academic research centers, governmental agencies, and other organizations also engage in competitive research activities. In the field of oncology, three oncolytic virus (OV) products have received global approval: Imlygic® by Amgen Inc. for melanoma in the USA; DELYTACT® by Daiichi Sankyo Company, Limited for malignant glioma in Japan; and Oncorine® by Shanghai Sunway Biotech Co., Ltd for late-stage refractory nasopharyngeal cancer in China. Additionally, Replimune, Inc. has submitted a biologics license application (BLA) resubmission for their OV RP1 in combination with nivolumab.
October 3, 2024
Navigating New Frontiers: Theriva Biologics Advances Cancer Therapy Research with Promising Clinical Trials In the rapidly evolving landscape of oncology, clinical-stage companies are at the forefront of introducing innovative treatments aimed at addressing the pressing medical needs of patients suffering from cancer. One such entity making significant strides in this domain is Theriva Biologics (NYSE American: TOVX), a company dedicated to developing therapeutics designed for the treatment of cancer and related diseases. Recent announcements regarding two of its clinical trials the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients and the Phase...
May 23, 2024
In a groundbreaking development, Theriva Biologics, a leading clinical-stage company focused on cancer therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its lead clinical candidate VCN-01. VCN-01, when used in combination with gemcitabine and nab-paclitaxel, has shown promising results in improving progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma.The FDA s Fast Track Designation is a significant milestone that aims to expedite the development and review process of new drugs to treat serious conditions where there is an unmet medical need. This designation reflects the urgent requirement for ...
April 23, 2024
Biopharmaceutical company Theriva Biologics has recently announced encouraging topline data from an investigator-sponsored Phase 1 trial of intravitreal VCN-01, a therapeutic treatment used against refractory retinoblastoma in pediatric patients, according to official statements. The study, conducted in collaboration with the reputed Sant Joan de Du-Barcelona Childrens Hospital (SJD), has been declared a success by the Study Monitoring Committee.Retinoblastoma is a type of eye cancer that mostly affects children, progressing rapidly from the retina to other parts of the body. Refractory Retinoblastoma refers to cases where the cancer does not respond or comes back after treatment. Targeting this form, VCN-01...
International Stem Cell Corporation Share Performance
+132.86%
This Year
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.
Hookipa Pharma Inc. is a biotechnology company that focuses on developing immunotherapeutics targeting infectious diseases and various forms of cancer. Their business model revolves around leveraging their proprietary technology platform, known as VaxWave, to design and manufacture a new class of immunotherapies. By collaborating with strategic partners and conducting clinical trials, Hookipa aims to bring these innovative treatments to market to improve patient outcomes and address unmet medical needs.
Sources:
Theriva Biologics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Theriva Biologics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
